Literature DB >> 28495986

PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations.

David D Waters1, Priscilla Y Hsue2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28495986     DOI: 10.1161/CIRCRESAHA.117.311015

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  6 in total

Review 1.  The Role of MicroRNAs in Hyperlipidemia: From Pathogenesis to Therapeutical Application.

Authors:  Yu Xiang; Li Mao; Mei-Ling Zuo; Gui-Lin Song; Li-Ming Tan; Zhong-Bao Yang
Journal:  Mediators Inflamm       Date:  2022-06-17       Impact factor: 4.529

2.  Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment

Authors:  Naveed Sattar; Adam Butterworth; Peter Würtz; Eeva Sliz; Johannes Kettunen; Michael Holmes; Clare Williams; Charles Boachie; Qin Wang; Minna Männikkö; Sylvain Sebert; Robin Walters; Kuang Lin; Lona Millwood; Robert Clarke; Liming Li; N Rankin; Paul Welsh; Christian Delles; J Jukema; Stella Trompet; Ian Ford; Markus Perola; Veikko Salomaa; Marjo-Riitta Järvelin; Zhengming Chen; Debbie Lawlor; Mika Ala-Korpela; John Danesh; George Smith
Journal:  Circulation       Date:  2018-11-27       Impact factor: 29.690

3.  Macrophages in Atherosclerosis Regression.

Authors:  Tessa J Barrett
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-11-14       Impact factor: 8.311

4.  Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

Authors:  E Sammons; J C Hopewell; F Chen; W Stevens; K Wallendszus; E Valdes-Marquez; R Dayanandan; C Knott; K Murphy; E Wincott; A Baxter; R Goodenough; M Lay; M Hill; S Macdonnell; G Fabbri; D Lucci; M Fajardo-Moser; S Brenner; D Hao; H Zhang; J Liu; B Wuhan; S Mosegaard; W Herrington; C Wanner; C Angermann; G Ertl; A Maggioni; P Barter; B Mihaylova; Y Mitchel; R Blaustein; S Goto; J Tobert; P DeLucca; Y Chen; Z Chen; A Gray; R Haynes; J Armitage; C Baigent; S Wiviott; C Cannon; E Braunwald; R Collins; L Bowman; M Landray
Journal:  Eur Heart J       Date:  2022-04-06       Impact factor: 35.855

5.  Physical Activity, Immune System, and the Microbiome in Cardiovascular Disease.

Authors:  Dawn M Fernandez; Jose C Clemente; Chiara Giannarelli
Journal:  Front Physiol       Date:  2018-06-29       Impact factor: 4.566

6.  Activation of microRNA-378a-3p biogenesis promotes hepatic secretion of VLDL and hyperlipidemia by modulating ApoB100-Sortilin1 axis.

Authors:  Tianpeng Zhang; Hongtao Shi; Ningning Liu; Jing Tian; Xiaoling Zhao; Clifford J Steer; Qinghua Han; Guisheng Song
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.